Russian drugmakers facing shortage of excipients

12 May 2022

Russian drug manufacturers and laboratories are faced with serious shortage of excipients, which is mainly due to serious interruptions in their deliveries to the Russian market, reports The Pharma Letter’s local correspondent.

Among these products are mainly dyes, stabilizers and thickeners, which prior to the February 24 invasion of Ukraine were mainly purchased by Russian companies in the European Union and the USA. The beginning of the military conflict between Ukraine and Russia has led to serious destruction of logistics chains and is associated with problems with supplies.

So far, a number of global producers have announced the official termination or suspension of their work in Russia. Among these companies are the German concern BASF and the Spanish firm Croda, as well as the Dutch IMCD group.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber



Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Today's issue

Company Spotlight

More Features in Generics